A common issue faced by drug discov5 Apr 2018 16:54
A common issue faced by drug discovery scientists who use conventional in vitro culture systems is their poor translatability to humans. To address this problem, Kirkstall developed the Quasi Vivo� System, which consists of interconnected cell-culture chambers and a peristaltic pump to create a continuous flow of media over cells. As a result, cultures are exposed to more physiologically relevant conditions, increasing the predictive value of in vitro experiments.
The Quasi Vivo� System is available with three different culture chambers (QV500, QV600, and QV900) to support a wide range of applications, including submerged cell culture, co-culture and modeling of air-liquid and liquid-liquid interfaces. Not only is the Quasi Vivo� System easy to set up, it also enables close monitoring of variables during an experiment. Furthermore, the large scale and user configurability of the Quasi Vivo� System allows assays to be performed that are not possible using microfluidic systems.
"Building on Lonza�s industry-respected cell-culture portfolio, the addition of the Quasi Vivo� System is an important step forward in advancing the use of primary cells in biomedical research," said Dr Maureen Bunger, Product Manager for ADME/Tox Solutions at Lonza. "Some of the limitations of primary cells, such as short life-spans and unstable phenotypes, are reduced when cells are cultured in a dynamic fluid system."
She added: "The Quasi Vivo� System, which has been developed by Kirkstall�s scientists over the last 10 years, is an important addition to our portfolio of more than 100 different primary cell types and specialized media solutions."
Kirkstall�s CEO, Dr Malcolm Wilkinson, commented: "The Quasi Vivo� System complements so many of Lonza�s existing products. It is already used in more than 70 labs worldwide across a wide variety of applications, and we look forward to working closely with Lonza to ensure the number of researchers benefiting from the system increases rapidly."
Sign In
Follow the stocks
